ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 8 of 42
УЖМБС 2017, 2(4): 50–53
Clinical Medicine

The Distribution of Genotypes of Polymorphism A1166C of the Angiotensin II Type 1 Receptor Gene in Patients with Arterial Hypertension in Combination with Non-Alcohol Fatty Liver Disease

Babak O., Zaitseva M.

The aim of the study is to estimate the distribution of genotypes of polymorphism A1166C of the angiotensin II type 1 receptor gene in patients with arterial hypertension and non-alcoholic fatty liver disease. Materials and methods. The study encompassed 125 patients with arterial hypertension. Additionally, the patients with arterial hypertension were divided into subgroups depending on presence of non-alcoholic fatty liver disease: group 1 was made up of patients with arterial hypertension and non-alcoholic fatty liver disease (n=55), group 2 included people without non-alcoholic fatty liver disease (n=60). The control group was represented by 20 apparently healthy people. The groups were compared according to age and sex. The diagnosis was made in accordance with valid orders of the Ministry of Health of Ukraine. All patients underwent common clinical and instrumental investigations. The study of polymorphism of the gene of the angiotensin II receptor of the first type was carried out by means of the method of polymerase chain reaction with electrophoretic detection of findings with the use of SNP- EXPRESS assay kit produced by LLC Lітех (Russian Federation). DNA purification out of the whole blood was performed owing to the commercial kit "DNA sorb-B" produced by InterLabService (Russian Federation) according to the instructions provided. Accuracy of genotype frequency distribution was assessed by means of correspondence of Hardy-Weinberg Equilibrium (pi2 + 2 pipj + pj2 = 1). In accordance with Helsinki Declaration, all patients were informed about clinical study and gave their consent to assess polymorphism of the gene in question. The obtained findings are represented in the form of average value ± standard deviation from average value (М±m). Statistical processing of the findings was carried out by means of Statistica package, version 6.0. In order to make an assessment of differences between groups in distribution, close to normal one, Pearson’s criterion was used. Differences in р<0.05 were considered to be statistically valid. Results. In the control group, the following distribution of the frequency of genotypes of polymorphism of the angiotensin II receptor of the first type gene (A1166C) occurred: the genotypes A/A, A/C and C/C had 12 (60 %), 5 (25 %) and 3 (15 %) persons, respectively. Genotypes A/A, A/C and C/C had 33 (55 %), 21 (35 %) and 6 (10 %) patients with hypertension respectively. As a result, it was found that in the group of patients with combined flow of arterial hypertension and non-alcoholic fatty liver disease, carriers of genotypes A/A, A/C and C/C were 16 (29.09 %), 29 (52.72 %) and 10 ( 18.19 %) respectively. Patients with arterial hypertension and non-alcoholic fatty liver disease were more likely to have an A/C genotype of 27.72 % (χ2 = 5.8; OR = 2.58 (95% CI: 1.46-9.95)) and less often A/A for 30.09 % (χ2 = 8.2; OR = 2.74 (95% CI: 1.22-10.46) than in the control group. Conclusions. According to our research, the genotype A/C of AGTR1 gene (A1166C) polymorphism was associated with a combined flow of arterial hypertension and non-alcoholic fatty liver disease, while the protective properties of the A/A genotype, on the contrary, were attenuated.

Keywords: arterial hypertension, non-alcoholic fatty liver disease, polymorphism of the angiotensin II type 1 receptor gene

Full text: PDF (Ukr) 190K

  1. Vyalov SS. Nealkogolnaya zhirovaya bolezn pecheni kak komponent metabolicheskogo sindroma: zhirovaya pechen i ateroskleroz. Consilium Medicum. 2012; 5 (14). 41–5. [Russian]
  2. Sidorchuk LP. Kompleksne likuvannya khvorikh na arterialnu gipertenziyu z urakhuvannyam polimorfizmu geniv: avtoref. diss. … doktora med. nauk. Abstr. Dr. Sci. (Med.). MOZ Ukrayini, KhNMU. Kharkiv, 2009. 40 s. [Ukrainian]
  3. Tseluyko VY, Yakovlyeva LM. Genetichni aspekti arterialnoyi gipertenziyi u khvorikh na ishemichnu khvorobu sertsya. Arterialnaya gipertenziya. 2013; 5 (31)Zh 16–20. [Russian]
  4. Liu Y, Zhuoma C, Shan G, Cui C, Hou S, Qin W, Cai D, et al. A1166C Polymorphism of the angiotensin II type 1 receptor gene and essential hypertension in han, tibetan and YI populations. Hypertens Res. 2002; 25: 515–21.
  5. Lapierre AV, Arce ME, Lopez JR, Ciuffo GM. Angiotensin II type 1 receptor A1166C GENE polymorphism and essential hypertension in San Luis. Biocell. 2006 Dec; 30 (3): 447–55.
  6. Bonnardeaux A, Davies E, Jeunemaitre X, Féry I, Charru A, Clauser E, Tiret L, Cambien F, Corvol P, Soubrier F. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension. 1994; 24: 63–9.
  7. Gainer JV, Hunley TE, Kon V, Nadeau JH, Muldowney JA 3rd, Brown NJ. Angiotensin II type I receptor polymorphism in African Americans lower frequency of the C-1166 variant. Biochem Mol Biol Int. 1997; 43: 227–31.
  8. Alvarez R, Reguero JR, Batalla A, Iglesias-Cubero G, Cortina A, Alvarez V, Coto E. Angiotensinconverting enzyme and angiotensin II receptor 1 polymorphismsassociation with early coronary disease. Cardiovasc Res.1998; 40: 375–9.
  9. Fletcher RW, Fletcher SW, Wagner EH. Clinical epidemiology. 3 Sub ed. Philadelphia: LippincottWilliams & Wilkins, 1996.
  10. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol. 2012; 10 (6): 646–50.